Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating Zilovertamab Vedotin (MK-2140) with standard of care in relapsed or refractory diffuse large B-cell lymphoma, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zilovertamab vedotin (zilovertamab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2, Phase 3 | Status: RECRUITING